

**Poonawalla Fincorp reported disappointing Q2 numbers with the credit cost of Rs9.1bn (including Rs6.7bn one-time provisioning on the STPL book) leading to the company posting a Rs4.7bn loss. The management provided comfort by stating that review of the entire portfolio is complete and there should not be any need for additional provision. The company unveiled 6 new products and its omnichannel phygital distribution that shall help it deliver 5-6x AUM growth in the next 6 years. With the Poonawalla name, strong capital adequacy, AAA rating at his disposal, and past baggage likely cleaned up, the new CEO, Arvind, is trying to build the franchise by hiring competent top and middle management, expanding product and distribution, and tightening the risk management. However, this strategy should moderate profitability over the medium term on account of higher opex, and the execution of this ambitious plan amid tightening regulatory environment and heightened competition will be a daunting task. We reiterate our REDUCE rating on the stock with revised Sep-25E TP of Rs240 (vs Rs400 earlier), implying FY26E P/BV of 2x.**

**Poonawalla Fincorp: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Net profits	5,849	20,560	3,031	11,202	13,930
AUM growths (%)	40.1	54.9	31.0	35.0	35.0
NII growths (%)	28.7	59.5	31.2	28.9	28.6
NIMs (%)	8.8	9.5	8.9	8.6	8.2
PPOP growth (%)	35.0	127.1	8.9	33.2	29.4
Adj. EPS (Rs)	7.6	10.8	3.9	14.5	18.1
Adj. EPS growth (%)	86.8	41.8	(63.7)	269.6	24.3
Adj. BV (Rs)	83.7	105.3	108.7	121.0	136.4
Adj. BVPS growth (%)	12.0	25.9	3.2	11.4	12.7
RoA (%)	3.7	4.0	1.1	3.1	2.9
RoE (%)	9.3	11.5	3.7	12.7	14.0
P/E (x)	38.9	27.4	75.5	20.4	16.4
P/ABV (x)	3.6	2.8	2.7	2.5	2.2

Source: Company, Emkay Research

**Clean up of the past and preparation for the future, cost dearly in the present**

PFL reported a net loss of Rs4.7bn due to a sharp surge in credit cost to Rs9.1bn, owing to a one-time provision of Rs6.7bn on review of past STPL book. The operating expenses growing to 5.4% of AUM (from 3.9% a quarter earlier) were due to a one-time expense on investments for future growth of Rs0.7bn. GS3 spiked QoQ to 2.1% from 0.67%, but higher provisioning ensured NS3 remained flat QoQ to 0.33%. AUM growth moderated to 5% QoQ/40% YoY from 8%/52% in Q1, owing to a credit policy review reducing Personal Loan disbursements to 1/5<sup>th</sup> of the earlier run rate. **(Exhibits 1 and 4)**

**Expanding people, product, and distribution to achieve ambitious growth plans**

The management emphasized that they have done a comprehensive review of the entire portfolio and have decided to provide an additional one-time provision of Rs6.7bn on the STPL book. With the clean-up act done, the focus shifts toward building the organization for the future, which delivers 5-6x AUM growth profitably in the next 5 years. To achieve this ambitious target, the company has announced comprehensive plans to expand the product offering by adding 6 new products (Prime PL, Gold Loan, Consumer Durables, Shopkeeper Loan, Education Loan, and Used CV), adding branches for products (that require branch presence), and strengthening management and field-level manpower strength (already underway). To support growth, the management is also very clear about its Phygital strategy (a sharp departure from the earlier Digital only), focusing on ramping up branch infra for products like gold, while continuing to work with DSA, Call centre, App/Web-led Digital sourcing for many other products.


**Material cut in estimates; reiterate REDUCE with revised TP of Rs240**

To reflect the Q2 developments (credit cost and OpEx spike) and the management commentary on future growth and profitability (increased OpEx guidance), we have changed our estimates leading to 74%/28%/29% earnings cut over FY25/26/27E. We reiterate our REDUCE rating on the stock with revised downwards Sep-25E TP of Rs240 (Rs400 earlier), implying FY26E P/B of 2x. Despite the recent correction, the stocks are currently trading on relatively richer valuation of FY26E P/B of 2.5x. While we view the new management team and their plan as a more sustainable one, the investors will prefer to watch from the fences over the next few quarters as: 1. Execution of ambitious growth plan has to be observed closely for progress, as the competitive and regulatory landscape appear difficult; 2. Given the outcome of past scorching growth phase cycle leading to ~4% true credit cost over FY21-25E, the investors will take time before differentiating current growth from the past. Against this backdrop, PFL shares are likely going to underperform in the near-to-medium term.

Target Price – 12M	Sep-25
Change in TP (%)	(40.0)
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(19.2)
CMP (25-Oct-24) (Rs)	297.1

Stock Data	Ticker
52-week High (Rs)	520
52-week Low (Rs)	287
Shares outstanding (mn)	777.7
Market-cap (Rs bn)	231
Market-cap (USD mn)	2,748
Net-debt, FY24E (Rs mn)	1,588
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	900.2
ADTV-3M (USD mn)	10.7
Free float (%)	-
Nifty-50	24,181
INR/USD	84.1
<b>Shareholding, Sep-24</b>	
Promoters (%)	61.9
FPIs/MFs (%)	7.7/10.6

Price Performance			
(%)	1M	3M	12M
Absolute	(26.5)	(18.8)	(16.4)
Rel. to Nifty	(20.9)	(18.0)	(33.9)



**Avinash Singh**  
 avinash.singh@emkayglobal.com  
 +91 22 6612 1327

**Kishan Rungta**  
 kishan.rungta@emkayglobal.com  
 +91 22 6624 2490

## Exhibit 1: Actual vs estimate

(Rs mn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	QoQ	YoY	2QFY25E	Var
NII	4,746	4,907	5,625	5,761	5,592	-2.9%	21.4%	6,146	-9.0%
Total income	5,292	5,501	6,407	6,758	6,449	-4.6%	27.7%	7,099	-9.2%
Opex	1,929	1,998	2,313	2,417	3,610	49.4%	25.3%	2,561	41.0%
PPOP	3,363	3,502	4,094	4,341	2,839	-34.6%	29.1%	4,538	-37.4%
Provision	288	(65)	239	445	9,144	1956.6%	54.4%	715	1178.7%
PBT	3,075	3,568	3,855	3,896	(6,305)	-261.8%	26.7%	3,823	-264.9%
PAT	12,589	2,651	3,317	2,916	(4,710)	-261.5%	-76.8%	2,841	-265.8%
Adj PAT	2,306	2,651	3,317	2,916	(4,710)	-261.5%	26.5%	2,841	-265.8%
AUM	202,150	219,460	250,030	269,720	283,960	5.3%	33.4%	291,298	-2.5%
Credit cost	0.61%	-0.12%	0.41%	0.68%	13.21%	1253bps	8bps	1.02%	1219bps
GS3	1.36%	1.33%	1.16%	0.67%	2.10%	143bps	-69bps	1.2%	90bps
NS3	0.72%	0.70%	0.59%	0.32%	0.33%	1bps	-40bps	0.6%	-29bps
PCR	47%	47%	49%	52%	84%	3205bps	504bps	50%	3429bps

Source: Company, Emkay Research

## Exhibit 2: Changes in Estimates

Y/E Mar (Rs mn)	FY25E			FY26E			FY27E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
AUM	330,040	327,539	-0.8%	445,553	442,178	-0.8%	601,497	596,940	-0.8%
Disbursement	392,810	392,810	0.0%	479,228	479,228	0.0%	599,036	599,036	0.0%
Net Interest Income	28,124	25,573	-9.1%	36,786	32,951	-10.4%	47,888	42,370	-11.5%
Operating expenses	10,993	12,324	12.1%	14,060	15,218	8.2%	17,899	19,197	7.3%
PPOP	19,023	15,134	-20.4%	25,168	20,159	-19.9%	32,926	26,090	-20.8%
Credit cost	3,147	11,055	251.2%	4,353	5,082	16.7%	6,478	7,342	13.3%
PAT	11,796	3,031	-74.3%	15,465	11,202	-27.6%	19,651	13,930	-29.1%
Adj PAT	11,796	3,031	-74.3%	15,465	11,202	-27.6%	19,651	13,930	-29.1%
Adj EPS (Rs)	15.3	3.9	-74.3%	20.1	14.5	-27.6%	25.5	18.1	-29.1%
Networth	91,190	83,740	-8.2%	104,336	93,262	-10.6%	121,038.9	105,102	-13.2%
BVPS (Rs)	118.3	108.7	-8.2%	135.4	121.0	-10.6%	157.1	136.4	-13.2%
AUM growth	32.0%	31.0%	-100bps	35.0%	35.0%	0bps	35.0%	35.0%	0bps
NIM	9.7%	8.9%	-84bps	9.5%	8.6%	-92bps	9.1%	8.2%	-99bps
Opex-to-AUM ratio	3.8%	4.3%	48bps	3.6%	4.0%	33bps	3.4%	3.7%	28bps
Cost-to-Income ratio	36.6%	44.9%	826bps	35.8%	43.0%	717bps	35.2%	42.4%	717bps
Credit Cost	1.1%	3.8%	274bps	1.1%	1.3%	20bps	1.2%	1.4%	18bps
ROA	4.2%	1.1%	-315bps	4.2%	3.1%	-111bps	4.0%	2.9%	-114bps
ROE	13.7%	3.7%	-1001bps	15.8%	12.7%	-316bps	17.4%	14.0%	-339bps

Source: Company, Emkay Research

## Exhibit 3: Valuation matrix

	CMP/TP (Rs)	Upside	Mkt Cap (Rs bn)	P/BV (x)			P/E (x)			RoA (%)			RoE (%)			Book Value (Rs)			Adj EPS (Rs)		
				FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY24E	FY25E	FY26E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
At current market price	297	-19.2%	305.9	2.73	2.45	2.18	75.52	20.43	16.43	1.10	3.10	2.89	3.68	12.66	14.04	109	121	136	3.9	14.5	18.1
AT target price	240			2.21	1.98	1.76	61.02	16.51	13.28	1.10	3.10	2.89	3.68	12.66	14.04	109	121	136	3.9	14.5	18.1

Source: Company, Emkay Research

**Exhibit 4: Quarterly result snapshot**

Particulars (Rs mn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	QoQ chg	YoY chg
Interest Income	6,901	7,144	8,436	8,962	9,107	1.6%	32.0%
Interest Expenses	2,155	2,237	2,811	3,201	3,516	9.8%	63.1%
NII	4,746	4,907	5,625	5,761	5,592	-2.9%	17.8%
Other Income	547	594	782	997	858	-13.9%	56.9%
Net Operating Income	5,292	5,501	6,407	6,758	6,449	-4.6%	21.9%
Operating Expenses	1,929	1,998	2,313	2,417	3,610	49.4%	87.1%
PPOP	3,363	3,502	4,094	4,341	2,839	-34.6%	-15.6%
Provisions	288	(65)	239	445	9,144	1956.6%	3076.0%
Credit costs	0.61%	-0.12%	0.41%	0.68%	13.21%	1253bps	1261bps
Extraordinary items	12,212	-	-	-	-		
Profit Before Tax	15,287	3,568	3,855	3,896	(6,305)	-261.8%	-141.2%
Tax	2,698	916	538	980	(1,594)	-262.6%	-159.1%
Tax rate	17.7%	25.7%	13.9%	25.2%	25.3%		
PAT	12,589	2,651	3,317	2,916	(4,710)	-261.5%	-137.4%
Adj PAT	2,306	2,651	3,317	2,916	(4,710)	-261.5%	-304.3%
GS3	1.36%	1.33%	1.16%	0.67%	2.10%	143bps	74bps
NS3	0.72%	0.70%	0.59%	0.32%	0.33%	1bps	-39bps
PCR	47.2%	47.3%	49.4%	52.2%	84.3%	3205bps	3709bps
AUM	202,150	219,460	250,030	269,720	283,960	5.3%	40.5%
Disbursement	78,070	87,310	96,880	74,000		-100.0%	-100.0%
Networth	77,811	80,750	81,164	83,700	80,150	-4.2%	3.0%

Source: Company, Emkay Research

**Exhibit 5: AUM Trend**

(Rs bn)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
AUM (Rs bn)	126	132	139	161	178	202	219	250	270	284
Growth QoQ	7%	4%	6%	16%	10%	14%	9%	14%	8%	5%
Growth YoY	21%	17%	28%	37%	41%	54%	58%	55%	52%	40%

Source: Company, Emkay Research


**Exhibit 6: Disbursement trend**

(Rs bn)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Disbursement (Rs bn)	29	31	33.7	63.7	70.6	78.1	87.3	96.9	74.0	79.9
Growth QoQ	14%	7%	8%	89%	11%	11%	12%	11%	-24%	8%
Growth YoY	95%	42%	157%	151%	143%	151%	159%	52%	5%	2%

Source: Company, Emkay Research


### Result in charts

**Exhibit 7: AUM grows by 5% QoQ**




Source: Company, Emkay Research

**Exhibit 8: AUM mix**




Source: Company, Emkay Research

**Exhibit 9: Balanced secured and unsecured AUM mix**




Source: Company, Emkay Research

**Exhibit 10: Disbursement grew 8% QoQ**




Source: Company, Emkay Research

**Exhibit 11: Yields witness slight moderation**




Source: Company, Emkay Research

**Exhibit 12: Margins dip during the quarter**




Source: Company, Emkay Research

**Exhibit 13: Opex increases significantly on a sequential basis**




Source: Company, Emkay Research

**Exhibit 14: Credit cost increased materially on a sequential basis**




Source: Company, Emkay Research

**Exhibit 15: Asset quality experiences deterioration**



Source: Company, Emkay Research


**Exhibit 16: ROA/ROE trend**



Source: Company, Emkay Research


### Story in charts

**Exhibit 17: We expect AUM to grow in the 30-35% range over FY25-27E**




Source: Company, Emkay Research

**Exhibit 18: Strong disbursement across the product segment**




Source: Company, Emkay Research

**Exhibit 19: Yield and CoFs expected to be stable**




Source: Company, Emkay Research

**Exhibit 20: We expect some impact on NIMs, as the company focus is on the prime and secured product going forward**




Source: Company, Emkay Research

**Exhibit 21: Opex-to-AUM to see increase in margin as the company continues to invest in expansion and manpower**




Source: Company, Emkay Research

**Exhibit 22: We expect some pressure on credit cost owing to the unseasoned STPL book**




Source: Company, Emkay Research

**Exhibit 23: Overall asset quality to improve in FY26-27E**



Source: Company, Emkay Research

**Exhibit 24: ROA/ROE trend**



Source: Company, Emkay Research

## Poonawalla Fincorp: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	18,169	29,041	39,518	52,665	70,318
Interest Expense	5,953	9,551	13,945	19,714	27,948
<b>Net interest income</b>	<b>12,217</b>	<b>19,490</b>	<b>25,573</b>	<b>32,951</b>	<b>42,370</b>
NII growth (%)	28.7	59.5	31.2	28.9	28.6
Non interest income	1,931	2,478	1,885	2,426	2,918
<b>Total income</b>	<b>14,148</b>	<b>21,967</b>	<b>27,458</b>	<b>35,377</b>	<b>45,287</b>
Operating expenses	8,031	8,074	12,324	15,218	19,197
<b>PPOP</b>	<b>6,117</b>	<b>13,894</b>	<b>15,134</b>	<b>20,159</b>	<b>26,090</b>
PPOP growth (%)	35.0	127.1	8.9	33.2	29.4
Provisions & contingencies	(1,337)	720	11,055	5,082	7,342
<b>PBT</b>	<b>7,453</b>	<b>13,173</b>	<b>4,079</b>	<b>15,077</b>	<b>18,748</b>
Extraordinary items	212	12,212	0	0	0
Tax expense	1,816	4,826	1,048	3,875	4,818
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>5,849</b>	<b>20,560</b>	<b>3,031</b>	<b>11,202</b>	<b>13,930</b>
PAT growth (%)	99.5	251.5	(85.3)	269.6	24.3
<b>Adjusted PAT</b>	<b>5,637</b>	<b>8,348</b>	<b>3,031</b>	<b>11,202</b>	<b>13,930</b>
<b>Diluted EPS (Rs)</b>	<b>7.4</b>	<b>26.9</b>	<b>4.0</b>	<b>14.6</b>	<b>18.2</b>
Diluted EPS growth (%)	80.0	265.0	(85.3)	269.6	24.3
<b>DPS (Rs)</b>	<b>2.0</b>	<b>2.0</b>	<b>0.6</b>	<b>2.2</b>	<b>2.7</b>
<b>Dividend payout (%)</b>	<b>26.3</b>	<b>7.5</b>	<b>15.0</b>	<b>15.0</b>	<b>15.0</b>
Effective tax rate (%)	24.4	36.6	25.7	25.7	25.7
Net interest margins (%)	8.8	9.5	8.9	8.6	8.2
Cost-income ratio (%)	56.8	36.8	44.9	43.0	42.4
PAT/PPOP (%)	92.2	148.0	20.0	55.6	53.4
Shares outstanding (mn)	768.0	770.6	770.6	770.6	770.6

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
<b>Asset quality</b>					
GNPL - Stage 3	2,251	2,685	7,245	6,113	5,502
NNPL - Stage 3	1,210	1,359	1,449	1,223	1,100
GNPL ratio - Stage 3 (%)	1.4	1.2	2.4	1.5	1.0
NNPL ratio - Stage 3 (%)	0.8	0.6	0.5	0.3	0.2
ECL coverage - Stage 3 (%)	46.3	49.4	80.0	80.0	80.0
ECL coverage - 1 & 2 (%)	1.2	3.8	1.1	0.9	0.8
Gross slippage - Stage 3	0	0	0	0	0
Gross slippage ratio (%)	0.0	0.0	0.0	0.0	0.0
Write-off ratio (%)	7.0	7.6	3.5	3.9	4.1
Total credit costs (%)	(1.0)	0.4	3.8	1.3	1.4
NNPA to networth (%)	1.9	1.7	1.7	1.3	1.0
<b>Capital adequacy</b>					
Total CAR (%)	38.9	0.0	0.0	0.0	0.0
Tier-1 (%)	37.7	0.0	0.0	0.0	0.0
<b>Miscellaneous</b>					
Total income growth (%)	33.7	55.3	25.0	28.8	28.0
Opex growth (%)	32.8	0.5	52.6	23.5	26.1
PPOP margin (%)	4.4	6.8	5.2	5.2	5.0
Credit costs-to-PPOP (%)	(21.9)	5.2	73.0	25.2	28.1
Loan-to-Assets (%)	84.5	91.7	92.1	93.8	95.1
Yield on loans (%)	13.1	14.1	13.7	13.7	13.5
Cost of funds (%)	6.7	7.3	7.6	7.5	7.5
Spread (%)	6.5	6.8	6.1	6.2	6.0

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	1,536	1,541	1,541	1,541	1,541
Reserves & surplus	62,711	79,623	82,199	91,721	1,03,561
<b>Net worth</b>	<b>64,247</b>	<b>81,164</b>	<b>83,740</b>	<b>93,262</b>	<b>1,05,102</b>
<b>Borrowings</b>	<b>1,11,196</b>	<b>1,50,801</b>	<b>2,16,176</b>	<b>3,09,525</b>	<b>4,35,766</b>
<b>Other liabilities &amp; prov.</b>	<b>4,775</b>	<b>8,397</b>	<b>9,237</b>	<b>10,160</b>	<b>11,176</b>
<b>Total liabilities &amp; equity</b>	<b>180,218</b>	<b>240,362</b>	<b>309,153</b>	<b>412,947</b>	<b>552,045</b>
Net loans	1,52,295	2,20,464	2,84,850	3,87,431	5,24,734
Investments	5,101	8,783	9,662	10,628	11,159
Cash, other balances	6,574	2,685	5,693	5,386	6,057
<b>Interest earning assets</b>	<b>1,63,970</b>	<b>2,31,933</b>	<b>3,00,205</b>	<b>4,03,445</b>	<b>5,41,950</b>
Fixed assets	2,117	1,944	2,138	2,352	2,587
Other assets	5,934	6,485	6,810	7,150	7,508
<b>Total assets</b>	<b>1,72,021</b>	<b>2,40,362</b>	<b>3,09,153</b>	<b>4,12,947</b>	<b>5,52,045</b>
BVPS (Rs)	83.7	105.3	108.7	121.0	136.4
Adj. BVPS (INR)	83.7	105.3	108.7	121.0	136.4
Gross loans	1,56,250	2,30,454	3,01,895	4,07,558	5,50,203
<b>Total AUM</b>	<b>1,61,430</b>	<b>2,50,030</b>	<b>3,27,539</b>	<b>4,42,178</b>	<b>5,96,940</b>
On balance sheet	1,56,250	2,30,454	3,01,895	4,07,558	5,50,203
Off balance sheet	5,180	19,576	25,645	34,620	46,737
Disbursements	1,57,510	3,32,890	3,92,810	4,79,228	5,99,036
Disbursements growth (%)	109.4	111.3	18.0	22.0	25.0
Loan growth (%)	42.6	44.8	29.2	36.0	35.4
AUM growth (%)	40.1	54.9	31.0	35.0	35.0
Borrowings growth (%)	65.3	35.6	43.4	43.2	40.8
Book value growth (%)	12.0	25.9	3.2	11.4	12.7

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	38.9	27.4	75.5	20.4	16.4
P/B (x)	3.6	2.8	2.7	2.5	2.2
P/ABV (x)	3.6	2.8	2.7	2.5	2.2
P/PPOP (x)	4.9	2.1	2.0	1.5	1.1
Dividend yield (%)	0.7	0.7	0.2	0.7	0.9
<b>DuPont-RoE split (%)</b>					
NII/avg AUM	8.8	9.5	8.9	8.6	8.2
Other income	1.2	0.7	0.7	0.6	0.6
Securitization income	0.0	0.0	0.0	0.0	0.0
Opex	2.1	1.8	2.0	1.9	1.9
Employee expense	3.7	2.2	2.2	2.0	1.8
<b>PPOP</b>	<b>4.4</b>	<b>6.8</b>	<b>5.2</b>	<b>5.2</b>	<b>5.0</b>
Provisions	(1.0)	0.4	3.8	1.3	1.4
Tax expense	1.3	2.3	0.4	1.0	0.9
<b>RoAUM (%)</b>	<b>4.1</b>	<b>10.0</b>	<b>1.0</b>	<b>2.9</b>	<b>2.7</b>
Leverage ratio (x)	2.3	2.8	3.5	4.3	5.2
<b>RoE (%)</b>	<b>9.3</b>	<b>11.5</b>	<b>3.7</b>	<b>12.7</b>	<b>14.0</b>
<b>Quarterly data</b>					
Rs mn, Y/E Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25
NII	4,746	4,907	5,625	5,761	5,592
NIM(%)	10.0	9.3	9.6	8.9	8.1
PPOP	3,363	3,502	4,094	4,341	2,839
PAT	12,589	2,651	3,317	2,916	(4,710)
EPS (Rs)	16.39	3.45	4.30	3.79	(6.10)

Source: Company, Emkay Research




**RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
04-Oct-24	395	400	Reduce	Avinash Singh
02-Sep-24	388	410	Reduce	Avinash Singh
20-Aug-24	400	410	Reduce	Avinash Singh
23-Jul-24	391	410	Reduce	Avinash Singh
04-Jul-24	419	440	Reduce	Avinash Singh
05-Jun-24	435	450	Reduce	Avinash Singh
30-Apr-24	491	450	Reduce	Avinash Singh
06-Apr-24	497	450	Reduce	Avinash Singh
18-Mar-24	472	440	Reduce	Avinash Singh
19-Jan-24	504	440	Reduce	Avinash Singh
05-Jan-24	459	440	Reduce	Avinash Singh
30-Nov-23	409	430	Add	Avinash Singh
21-Oct-23	377	430	Buy	Avinash Singh
25-Jul-23	380	430	Buy	Avinash Singh
08-Jul-23	362	430	Buy	Avinash Singh
30-Jun-23	341	430	Buy	Avinash Singh

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of October 27, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of October 27, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 27, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.